Further commentary in @RheumJnl from Peter Taylor – definitely a space to watchhttps://t.co/74St0w4DmS
— David Liew (@drdavidliew) June 16, 2019
Pilot vagal nerve stimulation for RA: interesting with clinical and immunological response, but surgical complications and lack of imaging data as yet. Also 4x/day worse than daily: too often might breed resistance? Looking forward to seeing more #EULAR2019 LB0009 @RheumNow pic.twitter.com/VZCl0RBlbq
— David Liew (@drdavidliew) June 15, 2019
It’s been a fantastic meeting – this is me, signing off from #EULAR2019 in Madrid! @RheumNow https://t.co/iYAcClaFMR pic.twitter.com/JQkXXNqdVN
— David Liew (@drdavidliew) June 15, 2019
That’s a wrap! Thank you to all delegates, speakers, submitters and exhibitors for making #EULAR2019 unforgettable! pic.twitter.com/RSa6DkCPt1
— EULAR (@eular_org) June 15, 2019
And off we go. Thank you #EULAR2019. Thank you #Madrid. What a beautiful city. We enjoyed seeing our friends on this side of the planet for a change. We look forward to Frankfurt 2020. Adiós! pic.twitter.com/vT8bURmkpJ
— J Rheum (@jrheum) June 16, 2019
Safety and Immunogenicity is one of nine educational videos available in the "Therapeutic Update: Biosimilars in Rheumatology" video series, sponsored by Sandoz, Inc. and now available on RheumNow. https://t.co/1vmnEJqOSi #sponsored #biosimilars
— Dr. John Cush (@RheumNow) June 17, 2019
Dr. Dinesh Khanna discusses the pulmonary outcomes of tocilizumab is systemic sclerosis (focuSSed trial). #EULAR2019 OP0245 pic.twitter.com/KvxoPhvyS6
— Dr. John Cush (@RheumNow) June 17, 2019
Presentation today at ATS #ATS2019. 1. early diffuse SSc. 2. 64% have ILD-recruited for elevated acute phase reactants. 3. treated with Tocilizumab vs. placebo for 48 wks EARLY SSc; elevated acute phase reactants; anti-IL-6 inhibition–> PRESERVATION OF ILD pic.twitter.com/63lwR1G0Cp
— Dr. Dinesh Khanna (@sclerodermaUM) May 20, 2019
Going beyond scleroderma. 1. Tanezumab is effective for OA related pain and no new safety concerns. #EULAR2019 pic.twitter.com/Uohex1uybS
— Dr. Dinesh Khanna (@sclerodermaUM) June 15, 2019
Low dose rituximab for retreatnent of RA. —6 month trial —RCT 1000 mg or 500 mg or 200 mg single dose. —there were more flares with low dose but less SI. — DAS 28 response was similar #EULAR2019
— Dr. Dinesh Khanna (@sclerodermaUM) June 15, 2019
Exercise program 30 min 12w (combination of generalised upper limb and specific hand exercises) helps to improve pain, function, dexterity, QOL over time more so than controlled group #eular2019 @RheumNow
— Alberta Hoi (@tuna0sashimi) June 14, 2019
MTX withdrawal in tofacitinib MR 11mg ORAL shift 1y study @week 24, MTX blindly withdrawal for pt achieved LDA (CDAI <=10) n>200 each arm no difference between arms consistent with anecdotal evidence of how pt can withdraw MTX in real life. #eular2019 @RheumNow
— Alberta Hoi (@tuna0sashimi) June 15, 2019
FUTURE 5 secukinumab in PsA placebo arm only 12w. Week 52 pt can increase doses from 150mg to 300mg. 2y data presented. Small incremental response when dose is escalated, and radiographic progression is low. #eular2019 @RheumNow
— Alberta Hoi (@tuna0sashimi) June 15, 2019
Vagal nerve stimulation for management of RA. Effective in refractory RA #EULAR2019 pic.twitter.com/petEUKty7v
— Dr. Dinesh Khanna (@sclerodermaUM) June 15, 2019
Can implanting vagal nerve stimulator in tough to treat RA pts work? Could theoretically decrease TNF. Small RCT. Maybe. Daily vagal stimulation May work in some. LB0009 #EULAR2019 @RheumNow pic.twitter.com/mqtcFCEie5
— Janet Pope (@Janetbirdope) June 15, 2019
#eular2019 H2H abatacept vs adalimumab prev study “AMPLE” showed similar efficacy (single blinded RA <2y study). Now “Early AMPLE” study for seropositive RA with or without HLA shared epitope confirmed previous observation of superiority of ABA at 24w
— Alberta Hoi (@tuna0sashimi) June 15, 2019
— Mehreen (@MehreenSoomro) June 15, 2019
It is always an absolute privilege working with Iain
Looking forward to his stint as @eular_org President…his track record suggests there will be some innovations ahead!@Racegbn @iiiglasgow @UofGMVLS @imidbio https://t.co/932Iz9kayV
— Stefan Siebert (@StefanSiebert1) June 16, 2019
EULAR HIGHLIGHTS. Ixekizumab beats adalimumab in PsA on combined end pt of skin + joints due to high skin response #EULAR2019 @RheumNow
— Janet Pope (@Janetbirdope) June 16, 2019
EULAR Highlights. 2 new JAKs presented more RA data. Upadacitinib and Filgotinib. Safety of JAKs in meta-analysis -no new safety signals. Tofacitinib use in Corrona = TNFI except slightly more shingles. 7yr Baricitinib data good – no VTE in LTE #EULAR2019 @RheumNow
— Janet Pope (@Janetbirdope) June 16, 2019
Comparison of high and low iris acid levels in a large cohort of gout patients shows high SUA associated with more comorbidities and CKD, more colchicine & indocin use. #EULAR2019 SAT0435 pic.twitter.com/FvUU4Q6Ky9
— Dr. John Cush (@RheumNow) June 17, 2019
Dr. Peter Lipsky – 1 Million #Gout Patients & who cares for them. SAT0435 #EULAR2018 https://t.co/WfFR4tRf2p
— Dr. John Cush (@RheumNow) June 17, 2019
A very productive Mentor Mentee meeting with the best mentors and best mentees @EMEUNET #EULAR19 #Madrid pic.twitter.com/nLQkdnK0u3
— EMEUNET (@EMEUNET) June 16, 2019
See @RheumILD! We love Ritux!
— Isabelle Amigues, MD, MS, RhMSUS, human, mom etc (@isa75012) June 16, 2019